1. Measurable residual disease conversion rate with consolidation chemotherapy in acute myeloid leukemia.
- Author
-
Gaut, Daria, Oliai, Caspian, Boiarsky, Jonathan, Zhang, Shiliang, Salhotra, Amandeep, Azenkot, Tali, Kennedy, Vanessa E., Khanna, Vishesh, Olmedo Gutierrez, Karla, Shukla, Navika, Moskoff, Benjamin, Park, Gabriel, Afkhami, Michelle, Patel, Anand, Jeyakumar, Deepa, Mannis, Gabriel, Logan, Aaron C., Jonas, Brian A., and Schiller, Gary
- Subjects
CONSOLIDATION chemotherapy ,ACUTE myeloid leukemia ,CANCER remission ,HEMATOPOIETIC stem cell transplantation ,DISEASE remission - Abstract
The rate of MRD clearance in AML with standard consolidation chemotherapy is not well defined. A multi-institution retrospective analysis was performed on 107 consecutively treated AML patients in morphologic complete remission with detectable MRD post-induction therapy who received standard chemotherapy consolidation. In response to standard intermediate/high-dose cytarabine consolidation therapy, 26 of 60 patients (43.3%) with MRD threshold of detection of at least 0.1% converted to MRD-negative status (undetectable with assay used), and 6 of 47 patients (12.8%) with MRD threshold of detection > 0.1% converted to MRD-negative status. Multivariable logistic regression for patients with MRD threshold of detection of at least 0.1% showed that, when controlling for age, ELN risk category, dose of cytarabine, and use of a combination agent, treatment with 1 cycle of consolidation cytarabine versus ≥2 cycles decreased the odds of conversion of AML to MRD-negative (OR = 0.24, 95% CI 0.07–0.85, p = 0.03). [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF